Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 607-614

  Xu, Lu ^a   Zuch, Christina L ^a   Lin, Yvonne S ^a,b   Modi, Nishit B ^a,c   Lum, Bert L ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; PACLITAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MONKEY; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CISPLATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; MACACA FASCICULARIS; MALE; PACLITAXEL;

EID: 38049001949     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0513-9     Document Type: Article

References (35)

1. Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19:331-358
2. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocrinol Rev 18:1-22
3. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(29):841-844
4. Kabbinavar FF, Wong JT, Ayala RE et al (1995) The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 36:488 (abstract 2906)
5. Borgström P, Gold DP, Hillan KJ et al (1999) Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19(5b):4203-4214
6. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61(8):3369-3372
7. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671-680
8. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1):2-10
9. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
11. Reddy GK (2005) The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4(5):300-301
12. Tyagi P (2005) Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin Lung Cancer 6(5):276-278
13. Laskin JJ, Sandler AB (2005) First-line treatment for advanced non-small-cell lung cancer. Oncology 19(13):1671-1676
14. Miller KD (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3(6):421-422
15. Muggia FR, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitxel versus cisplatin plus paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18(1):2349-2351
16. Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, Adamis AP, D'Amore PA (1996) Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 37(7):1334-1340
17. Hegedus L, van der Vijgh WJ, Klein I, Kerpel-Fronius S, Pinedo HM (1987) Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemother Pharmacol 20(3):211-212
18. Winer BJ (1971) Design and analysis of single-factor experiments, in statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, pp 149-260
19. Levene H (1960) Robust tests for equality of variances. In: Olkin I (ed) Contributions to probability and statistics. Stanford University Press, Stanford, pp 278-292
20. Dunnett CW (1964) New tables for multiple comparisons with a control. Biometrics 20:482-491
21. Winer BJ (1971) Analysis of covariance, in statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, pp 752-812
22. SAS Institute Inc (1989), SAS/STAT® User's Guide, Version 6, 4th edn, vol 2. SAS Institute Inc., Cary, p 909
23. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1):371-378
24. Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharm 57(6):756-763
25. Mitchell EP, Schein PS (1984) Gastrointestinal toxicology of chemotherapeutic agents. In: Perry MC, Yarbro JW (eds) Toxicity of chemotherapy. Grune and Stratton Inc., Orlando, pp 269-295
26. Hoogland HC (1984) Hemotologic complications of cancer chemotherapy. In: Perry MC, Yarbro JW (eds) Toxicity of chemotherapy. Grune and Stratton Inc., Orlando, pp 433-448
27. Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9(Suppl 1):19-26
28. Mulcahy MF, Benson AB 3rd (2005) Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5(7):997-1005
29. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26(3):690-696
30. Junghans RP (1997) Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16(1):29-57
31. Story CM, Mikulska JE, Simister NE (1994) A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 180(6):2377-2381
32. Simister NE, Mostov KE (1989) Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54(1):571-580
33. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of paclitaxel to 6 alpha-hydroxypaclitaxel by human cytochrome P450 2C8. Cancer Res 54(21):5543-5546
34. Vaishampayan U, Parchment RE, Jasti BR, Hussain M (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54(6A Suppl):22-29
35. Gaudreault J, Shiu V, Bricarello A, Christian BJ, Zuch CL, Mounho B (2005) Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. Int J Toxicol 24(5):357-363